CURED was featured in the Chancellor’s letter:
[…] in order to advance medicine and health, pharmaceutical companies often focus on what will make the most money, whereas medical schools and research centers rely on nearby patients. But what happens if a disease is new, uncommon, or concentrated in developing countries?
Immunology and molecular medicine professor Andrew Dillin faced this very conundrum. He and his lab found a promising new way to treat Leigh’s disease, a rare, fatal condition that mostly affects children and causes seizures, developmental delays, and heart and breathing problems. The science worked — but the pharmaceutical industry said no. There simply weren’t enough sick children to justify the cost.
Read the full feature here.